Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1

Abstract

Aim: Forkhead box M1 (FoxM1) is a transcription factor that plays important roles in the pathogenesis and progression of human cancers, including hepatocellular carcinoma (HCC). The aim of this study was to examine the involvement of FoxM1 in the anti-cancer action of sorafenib, a multikinase inhibitor, in human HCC cells. Methods: HCC cell lines HepG2 and HuH-7 were tested. Cell viability was examined using MTT assay and cell invasion was determined with Transwell migration assay. The relevant mRNA expression was determined with RT-PCR, and the proteins were detected using Western blotting and immunofluorescence assays. RNA interference was used to modify the expression of p53 and FoxM1. HuH-7 cell line xenograft mice were used for in vivo study, which were treated with sorafenib (40 mg/kg, po) daily for 3 weeks. Results: Sorafenib (2-20 μmol/L) inhibited the proliferation of the cells in dose-and time-dependent manners with an IC 50 value of nearly 6 μmol/L at 48 h. Sorafenib (6 μmol/L) markedly suppressed the cell invasion. Furthermore, sorafenib (2−6 μmol/L) dose-dependently decreased the expression of FoxM1, MMP-2, and Ki-67, and up-regulated that of p53 in the cells. Silencing p53 abolished the decrease of FoxM1 and increase of p53 in sorafenib-treated cells. Silencing FoxM1 significantly reduced the expression of MMP-2 and Ki-67, and enhanced the anti-proliferation action of sorafenib in the cells, whereas overexpression of FoxM1 increased the expression of MMP-2 and Ki-67, and abrogated the anti-proliferation action of sorafenib. In the xenograft mice, sorafenib administration decreased the tumor growth by 40%, and markedly increased the expression of p53, and decreased the expression of FoxM1, MMP-2, and Ki-67 in tumor tissues. Conclusion: Sorafenib inhibits HCC proliferation and invasion by inhibiting MMP-2 and Ki-67 expression due to up-regulation of P53 and suppressing FoxM1.

In vitro inhibitory effects of dihydromyricetin on human liver cytochrome P450 enzymes

“…The most common causes of herb-drug interactions are modification of the enzyme activity of cytochrome P450 enzymes, specifically through inhibitory effects. Inhibition of CYP enzymes in vivo may result in unexpected elevations in the plasma concentrations of concomitant drugs, leading to adverse effects (Hu et al 2015;Wei et al 2015). Therefore, regulatory authorities require preclinical (in vitro) and clinical (in vivo) interaction studies in drug development.…”

New insights into molecular diagnostic pathology of primary liver cancer: Advances and challenges

“…Studies have shown that the inhibition of HCC proliferation by sorafenib might be achieved through the upregulation of the p53 pathway and the inhibition of FoxM1 [24]. Therefore, FoxM1 might be used as a cell target for targeted drug therapy of HCC [25].…”

Caspase-2 deficiency accelerates chemically induced liver cancer in mice

“…[7][8][9][10] It has increasingly been recognised that apoptosis and compensatory proliferation are crucial for progression of certain cancers including HCC. [11][12][13] While loss of apoptosis would indirectly favour proliferation, this is not universally true, for example loss of PUMA, or hepatocyte-specific deletion of Bid, impedes HCC by preventing compensatory proliferation. [14][15][16][17][18][19][20] Metabolic state is another important regulator of HCC progression and there is increasing evidence that caspase-2 has a subtle role in regulating this process.…”